Share This Article:

Synthesis and Anticancer Activity of Mono-Carbonyl Analogues of Curcumin

Abstract Full-Text HTML Download Download as PDF (Size:279KB) PP. 113-123
DOI: 10.4236/jct.2013.41016    5,378 Downloads   9,481 Views   Citations

ABSTRACT

Curcumin has been reported to possess multifunctional bioactivities with low toxicity. However, the clinical application of curcumin has been significantly limited by its instability and poor metabolic property. Up to now, multiple approaches are being sought to overcome these limitations to obtaining “super curcumin”, and many analogues of curcumin have been designed and synthesized. In all of those analogues, a series of mono-carbonyl curcumin analogues deleting the β-diketone draw our attention. Since the seven-carbon β-diketone linker in curcumin may be responsible for its instability, the series of mono-carbonyl curcumin analogues deleting the β-diketone may be potential prodrug with improved pharmacokinetic and pharmacodynamic properties. This review just focuses on these more stable mono-carbonyl analogues of curcumin, and shows the new class of active structure by introducing the synthesis and anticancer activity of them.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Yin, X. Zheng, X. Yao, Y. Wang and D. Liao, "Synthesis and Anticancer Activity of Mono-Carbonyl Analogues of Curcumin," Journal of Cancer Therapy, Vol. 4 No. 1, 2013, pp. 113-123. doi: 10.4236/jct.2013.41016.

References

[1] I. Rahman, S. K. Biswas and P. A. Kirkham, “Regulation of Inflammation and Redoxsignaling by Dietarypolyphenols”, Biochemical Pharmacology, Vol. 72, No. 11, 2006, pp. 1439-1452. doi:10.1016/j.bcp.2006.07.004
[2] N. Tirkey, G. Kaur, G. Vij and K. Chopra, “Curcumin, a Diferuloylmethane, Attenuates Cyclosporine-Induced Renal Dysfunction and Oxidative Stress in Rat Kidneys,” BMC Pharmacology, Vol. 5, No. 15. 2005. doi:10.1186/1471-2210-5-15
[3] B. V. Reddy, J. S. Sundary, E. Balamurugan and V. P. Menon, “Prevention of Nicotine and Streptozotocin Treatment Induced Circulatory Oxidative Stress by Bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione in Diabetic Rats,” Molecular and Cellular Biochemistry, Vol. 331, No. 1-2, 2009, pp. 127-133. doi:10.1007/s11010-009-0150-1
[4] D. K. Agrawal and P. K. Mishra, “Curcumin and Its Analogues: Potential Anticancer Agents,” Medicinal Research Reviews, Vol. 30, No. 5, 2010, pp. 818-860. doi:10.1002/med.20188
[5] P. Basneta and N. Skalko-Basnet, “Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment,” Molecules, Vol. 16, No. 6, 2011, pp. 4567-4598. doi:10.3390/melecules16064567
[6] H. S. Na, M. H. Cha, D. R. Oh, C. W. Cho, J. H. Rhee and Y. R. Kim, “Protective Mechanism of Curcumin against Vibrio vulnificus Infection,” FEMS Immunology & Medical Microbiology, Vol. 63, No. 3, 2011, pp. 355-362. doi:10.1111/j.1574-695X.2011.00855.x
[7] A. Goel, A. B. Kunnumakkara and B. B. Aggarwal, “Curcumin as “Curecumin”: From Kitchen to Clinic,” Biochemical Pharmacology, Vol. 75, No. 4, 2008, pp. 787-809. doi:10.1016/j.bcp.2007.08.016
[8] R. A. Sharma, W. P. Steward and A. J. Gescher, “Pharmacokinetics and Pharmacodynamics of Curcumin,” Advances in Experimental Medicine and Biology, Vol. 595, 2007, pp. 453-470. doi:10.1007/978-0-387-46401-5_20
[9] M. H. Pan, T. M. Huang and J. K. Lin, “Biotransformation of Curcumin through Reduction and Glucuronidation in mice,” Drug Metabolism and Disposition, Vol. 27, No. 4, 1999, pp. 486-494. doi:0090-9556/99/2701-0486–494$02.00/0
[10] D. Youssef, C. E. Nichols, T. S. Cameron, J. Balzarini, E. D. Clercq and A. Jha, “Design, Synthesis, and Cytostatic Activity of Novel Cyclic Curcumin Analogues,” Bioorganic & Medicinal Chemistry Letters, Vol. 17, No. 20, 2007, pp. 5624-5629. doi:10.1016/j.bmcl.2007.07.079
[11] X. Qiu, Z. Liu, W. Y. Shao, X. Liu, D. P. Jing, Y. J. Yu, L. K. An, S. L.Huang, X. Z. Bu, Z. S. Huang and L. Q. Gu, “Synthesis and Evaluation of Curcumin Analogues as Potential Thioredoxin Reductase Inhibitors,” Bioorganic & Medicinal Chemistry, Vol. 16, No. 17, 2008, pp. 8035-8041. doi:10.1016/j.bmc.2008.07.054
[12] Q. Zhang, Y. Zhong, L. N. Yan, X. Sun, T. Gong and Z. R. Zhang, “Synthesis and Preliminary Evaluation of Curcumin Analogues as Cytotoxic Agents,” Bioorganic & Medicinal Chemistry Letters, Vol. 21, No. 3, 2011, pp. 1010-1014. doi:10.1016/j.bmcl.2010.12.020
[13] S. K. Dubey, A. K. Sharma, U. Narain, K. Misra and U. Pati, “Design, Synthesis and Characterization of Some Bioactive Conjugates of Curcumin with Glycine, Glutamic Acid, Valine and Demethylenated Piperic Acid and Study of Their Antimicrobial and Antiproliferative Properties,” European Journal of Medicinal Chemistry, Vol. 43, No. 9, 2008, pp. 1837-1846. doi:10.1016/j.ejmech.2007.11.027
[14] L. Lin, Q. Shi, A. K. Nyarko, K. F. Bastow, C. C. Wu, C. Y. Su, C. C. Y Shih and K. H. Lee, “Antitumor Agents. 250. Design and Synthesis of New Curcumin Analogues as Potential Anti-Prostate Cancer Agents,” Journal of Medicinal Chemistry, Vol. 49, No. 13, 2006, pp. 3963-3972. doi:10.1021/jm051043z
[15] J. A. Lenhart, X. Ling, R. Gandhi, T. L. Guo, P. M. Gerk, D. H. Brunzell and S. Zhang, “‘Clicked’ Bivalent Ligands Containing Curcumin and Cholesterol as Multifunctional Abeta Oligomerization Inhibitors: Design, Synthesis, and Biological Characterization,” Journal of Medicinal Chemistry, Vol. 53, No. 16, 2010, pp. 6198-6209. doi:10.1021/jm100601q
[16] J. Zhou, G. Geng, Q. Shi, F. Sauriol and J. H. Wu, “Design and Synthesis of Androgen Receptor Antagonists with Bulky Side Chains for Overcoming Antiandrogen Resistance,” Journal of Medicinal Chemistry, Vol. 52, No. 17, 2009, pp. 5546-5550. doi:10.1021/jm801218k
[17] Y. J. Wang, M. H. Pan, A. L. Cheng, L. I. Lin, Y. S. Ho, C. Y. Hsieh and J. K. Lin, “Stability of Curcumin in Buffer Solutions and Characterization of Its Degradation Products,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 15, No. 12, 1997, pp. 1867-1876. doi:10.1016/S0731-7085(96)02024-9
[18] M. A. Tomren, M. Masson, T. Loftsson and H. H. Tonnesen, “Studies on Curcumin and Curcuminoids XXXI. Symmetric and Asymmetric Curcuminoids: Stability, Activity and Complexation with Cyclodextrin,” International Journal of Pharmaceutics, Vol. 338, No. 1-2, 2007, pp. 27-34. doi:10.1016/j.ijpharm.2007.01.013
[19] G. D. Straganz, A. Glieder, L. Brecker, D. W. Ribbons and W. Steiner, “Acetylacetone-Cleaving Enzyme Dke: A Novel C-C-Bond-Cleaving Enzyme from Acinetobacter Johnsonii,” Biochemical Journal, Vol. 369, No. 3, 2003, pp. 573-581. doi:10.1042/BJ20021047
[20] M. J. C. Rosemonda, L. S. J. Williamsa, T. Yamaguchib, T. Fujishitac and J. S. Walsha, “Enzymology of a Carbonyl Reduction Clearance Pathway for the HIV Integrase Inhibitor, S-1360: Role of Human Liver Cytosolic Aldo-Keto Reductases,” Chemico-Biological Interactions, Vol. 147, No. 2, 2004, pp. 129-139. doi:10.1016/j.cbi.2003.12.001
[21] G. Grogan, “Emergent Mechanistic Diversity of Enzyme-Catalysed β-Diketone Cleavage,” Biochemical Journal, Vol. 388, No. 3, 2005, pp. 721-730. doi:10.1042/BJ20042038
[22] G. Liang, L. Shao, Y. Wang, C. Zhao, Y. Chu, J. Xiao, Y. Zhao, X. Li and S. Yang, “Exploration and Synthesis of Curcumin Analogues with Improved Structural Stability Both in Vitro and in Vivo as Cytotoxic Agents,” Bioorganic & Medicinal Chemistry, Vol. 17, No. 6, 2009, pp. 2623-2631. doi:10.1016/j.bmc.2008.10.044
[23] T. C. Hour, J. Chen, C. Y. Huang, J. Y. Guan, S. H. Lu and Y. S. Pu, “Curcumin Enhances Cytotoxicity of Chemotherapeutic Agents in Prostate Cancer Cells by Inducing p21WAF1/CIP1 and C/EBPβ Expressions and Suppressing NF-κB Activation,” The Prostate, Vol. 51, No. 3, 2002, pp. 211-218. doi:10.1002/pros.10089
[24] M. M. Chan, D. Fong, K. J. Soprano, W. F. Holmes and H. Heverling, “Inhibition of Growth and Sensitization to Cisplatin-Mediated Killing of Ovarian Cancer Cells by Polyphenolic Chemopreventive Agents,” Journal of Cellular Physiology, Vol. 194, No. 1, 2003, pp. 63-70. doi:10.1002/jcp.10186
[25] J. Y. Koo, H. J. Kim, K. O. Jung and K. Y. Park, “Curcumin Inhibits the Growth of AGS Human Gastric Carcinoma Cells In Vitro and Shows Synergism with 5-Fluorouracil,” Journal of Medicinal Food, Vol. 7, No. 2, 2004, pp. 117-121. doi:10.1089/1096620041224229
[26] M. Notarbartolo, P. Poma, D. Perri, L. Dusonchet, M. Cervello and N. D’Alessandro, “Antitumoreffects of Curcumin, Alone or in Combination with Cisplatin or Doxorubicin, on Humanhepaticcancer Cells. Analysis of Their Possiblerelationship to Changes in NF-kB Activation Levels and in IAP Gene Expression,” Cancer Letters, Vol. 224, No. 1, 2005, pp. 53-65. doi:10.1016/j.canlet.2004.10.051
[27] S. V. Bava, V. T. Puliappadamba, A. Deepti, A. Nair, D. Karunagaran and R. J. Anto, “Sensitization of Taxol-Induced Apoptosis by Curcumin Involves Down-Regulation of Nuclear Factor-κB and the Serine/Threonine Kinase Akt and Is Independent of Tubulin Polymerization,” The Journal of Biological Chemistry, Vol. 280, No. 8, 2005, pp. 6031-6038. doi:10.1074/jbc.M410647200
[28] B. B. Aggarwal, S. Shishodia, Y. Takada, S. Banerjee, R. A. Newman, C. E. Bueso-Ramos and J. E. Price, “Curcumin Suppresses the Paclitaxel-Induced Nuclear Factor-κB Pathway in Breast Cancer Cells and Inhibits Lung Metastasis of Human Breast Cancer in Nude Mice,” Clinical Cancer Research, Vol. 11, No. 20, 2005, pp. 7490-7498. doi:10.1158/1078-0432.CCR-05-1192
[29] S. L. Ari , L. Strier, D. Kazanov, L. M. Shapiro, H. D. Sobol , I. Pinchuk, B. Marian, D. Lichtenberg and N. Arber, “Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells,” Clinical Cancer Research, Vol. 11, 2005, pp. 6738-6744. doi:10.1158/1078-0432.CCR-05-0171
[30] S. Sen, H. Sharma and N. Singh, “Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway,” Biochemical and Biophysical Research Communications, Vol. 331, No. 4, 2005, pp. 1245-1252. doi:10.1016/j.bbrc.2005.04.044
[31] A. M. Kamat, G. Sethi and B. B. Aggarwal, “Curcumin Potentiates the Apoptotic Effects of Chemotherapeutic Agents and Cytokines through Down-Regulation of Nuclear Factor-κB and Nuclear Factor-κB-Regulated Gene Products in IFN-α-Sensitive and IFN-α-Resistant Human Bladder Cancer Cells,” Molecular Cancer Therapeutics, Vol. 6, No. 3, 2007, pp. 1022-1030. doi:10.1158/1535-7163.MCT-06-0545
[32] S. Lev-Ari, A. Vexler, A. Starr, M. Ashkenazy-Voghera, J. Greif, D. Aderka and R. Ben-Yosef, “Curcumin Augments Gemcitabine Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines,” Cancer Investigation, Vol. 25, No. 6, 2007, pp. 411-418. doi:10.1080/07357900701359577
[33] R. Kuttan, P. C. Sudheeran anf C. D. Josph, “Turmeric and Curcumin as Topical Agents in Cancer Therapy,” Tumori, Vol. 73, No. 1, 1987, pp. 29-31.
[34] R. A. Sharma, H. R. McLelland, K. A. Hill, C. R. Ireson, S. A. Euden, M. M. Manson, M. Pirmohamed, L. J. Marnett, A. J. Gescher and W. P. Steward, “Pharmacodynamic and Pharmacokinetic Study of Oral Curcuma Extract in Patients with Colorectal Cancer,” Clinical Cancer Research, Vol. 7, No. 7, 2001, pp. 1894-1900.
[35] N. Dhillon, B. B. Aggarwal, R. A. Newman, R. A. Wolff, A. B. Kunnumakkara, J. L. Abbruzzese, C. S. Ng, V. Badmaev and R. Kurzrock, “Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer,” Clinical Cancer Research, Vol. 14, 2008, pp. 4491-4499. doi:10.1158/1078-0432.CCR-08-0024
[36] M. B. Robert, F. Kwiatowski, M. Leheurteur, F. Gachon, E. Planchat, C. Abrial, M. A. Mouret-Reynier, X. Durando, C. Barthomeuf and P. Chollet, “Phase I Dose Escalation Trial of Docetaxel Plus Curcumin in Patients with Advanced and Metastatic Breast Cancer,” Cancer Biology & Therapy, Vol. 9, No. 1, 2010, pp. 8-14. doi:10.4161/cbt.9.1.10392
[37] H. Ide, S. Tokiwa, K. Sakamaki, K. Nishio, S. Isotani, S. Muto, T. Hama, H. Masuda and S. Horie, “Combined Inhibitory Effects of Soy Isoflavones and Curcumin on the Production of Prostate-Specific Antigen,” The Prostate, Vol. 70, No. 10, 2010, pp. 1127-1133. doi:10.1002/pros.21147
[38] T. Golombick, T. H. Diamond, V. Badmaev, A. Manoharan and R. Ramakrishna, “The Potential Role of Curcumin in Patients with Monoclonal Gammopathy of Undefined Significance—Its Effect on Paraproteinemia and the Urinary N-Telopeptide of Type I Collagen Bone Turnover Marker,” Clinical Cancer Research, Vol. 15, No. 18, 2009, pp. 5917-5922. doi:10.1158/1078-0432.CCR-08-2217
[39] K. Polasa, T. C. Raghuram, T. P. Krishna and K. Krishnaswamy, “Effect of Turmeric on Urinary Mutagens in Smokers,” Mutagenesis, Vol. 7, No. 2, 1992, pp. 107-109. doi:10.1093/mutage/7.2.107
[40] A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu, Y. F. Ho, T. S. Shen, J. Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, H. S. Yu, S. H. Jee, G. S. Chen, T. M. Chen, C. A. Chen, M. K. Lai, Y. S. Pu, M. H. Pan, Y. J. Wang, C. C. Tsai and C. Y. Hsieh, “Phase I Clinical Trial of Curcumin, a Chemopreventive Agent, in Patients with High-Risk or Pre-Malignant Lesions,” Anticancer Research, Vol. 21, No. 4B, 2001, pp. 2895-2900.
[41] B. Rai, J. Kaur, R. Jacobs and J. Singh, “Possible Action Mechanism for Curcumin in Pre-Cancerous Lesions Based on Serum and Salivary Markers of Oxidative Stress,” Journal of Oral Science, Vol. 52, No. 2, 2011, pp. 251-256. doi:10.2334/josnusd.52.251
[42] B. Wahlstrom and G. Blennow, “A Study on the Fate of Curcumin in the Rat,” Acta Pharmacologica et Toxicologica, Vol. 43, No. 2, 1978, pp. 86-92. doi:10.1111/j.1600-0773.1978.tb02240.x
[43] M. H. Pan, T. M. Huang and J. K. Lin, “Biotransformation of Curcumin through Reduction and Glucuronidation in Mice,” Drug Metabolism and Disposition, Vol. 27, No. 4, 1999, pp. 486-494.
[44] S. S. Sardjiman, M. S. Reksohadiprodjo, L. Hakim, H. Goot and H. Timmerman, “1,5-Diphenyl-1,4-pentadiene-3-ones and Cyclic Analogues as Antioxidative Agents. Synthesis and Structure-Activity Relationship,” European Journal of Medicinal Chemistry, Vol. 32, No. 7-8, 1997, pp. 625-630. doi:10.1016/S0223-5234(97)83288-6
[45] Z. Du, R. Liu, W. Shao, X. Mao, L. Ma, L. Gu, Z. Huang and A. S. C. Chan, “α-Glucosidase Inhibition of Natural Curcuminoids and Curcumin Analogs,” European Journal of Medicinal Chemistry, Vol. 41, No. 2, 2006, pp. 213-218. doi:10.1016/j.ejmech.2005.10.012
[46] K. Lee, F. H. A. Aziz, A. Syahida, F. Abas, K. Shaari, D. A. Israf and N. H. Lajis, “Synthesis and Biological Evaluation of Curcumin-Like Diarylpentanoid Analogues for Anti-In?ammatory, Antioxidant and Anti-Tyrosinase Activities,” European Journal of Medicinal Chemistry, Vol. 44, No. 8, 2009, pp. 3195-3200. doi:10.1016/j.ejmech.2009.03.020
[47] G. Liang, X. Li, L. Chen, S. Yang, X. Wu, E. Studer, E. Gurley, P. B. Hylemon, F. Ye, Y. Li and H. Zhou, “Synthesis and Anti-In?ammatory Activities of Mono-Carbonyl Analogues of Curcumin,” Bioorganic & Medicinal Chemistry Letters, Vol. 18, No. 4, 2008, pp. 1525-1529. doi:10.1016/j.bmcl.2007.12.068
[48] J. A. Quincoces Suarez, D. G. Rando, R. P. Santos, C. P. Gon?alves, E. Ferreira, J. E. Carvalho, L. Kohn, D. A. Maria, F. Faiao-Flores, D. Michalik, M. C. Marcucci and C. Vogel, “New Antitumoral Agents I: In Vitro Anticancer Activity and in Vivo Acute Toxicity of Synthetic 1,5-Bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadien-3-one and Derivatives,” Bioorganic & Medicinal Chemistry, Vol. 18, No. 17, 2010, pp. 6275-6281. doi:10.1016/j.bmc.2010.07.026
[49] H. Ligeret, S. Barthélémy, G. B. Doulakas, P. Carrupt, J. Tillement, S. Labidalle and D. Morin, “Fluoride Curcumin Derivatives: New Mitochondrial Uncoupling Agents,” FEBS Letters, Vol. 569, No. 1-3, 2004, pp. 37-42. doi:10.1016/j.febslet.2004.05.032
[50] O. Stoetzer, A. Pogrebniak, R. Pelka-Fleischer, M. Hasmann, W. Hiddemann and V. Nuessler, “Modulation of Apoptosis by Mitochondrial Uncouplers: Apoptosis Delaying Features Despite Intrinsic Cytotoxicity,” Biochemical Pharmacology, Vol. 63, No. 3, 2002, pp. 471-483. doi:10.1016/S0006-2952(01)00879-6
[51] B. K. Adams, E. M. Ferstl, M. C. Davis, M. Herold, S. Kurtkaya, R. F. Camalier, M. G. Hollingshead, G. Kaur, E. A. Sausville, F. R. Rickles, J. P. Snyder, De. C. Liotta and M. Shoji, “Synthesis and Biological Evaluation of Novel Curcumin Analogs as Anti-Cancer and Anti-Angiogenesis Agents,” Bioorganic & Medicinal Chemistr, Vol. 12, No. 14, 2004, pp. 3871-3883. doi:10.1016/j.bmc.2004.05.006
[52] A. Sun, M. Shoji , Y. J. Lu, D. C. Liotta and J. P. Snyder, “Synthesis of EF24 Tripeptide Chloromethyl Ketone: A Novel Curcumin-Related Anticancer Drug Delivery System,” Journal of Medicinal Chemistry, Vol. 49, No. 11, 2006, pp. 3153-3158. doi:10.1021/jm051141k
[53] A. L. Kasinski, Y. Du, S. L. Thomas, J. Zhao, S. Sun, F. R. Khuri, C. Y. Wang, M. Shoji, A. Sun, J. P. Snyder, D. Liotta and H. Fu, “Inhibition of IκB Kinase-Nuclear Factor-κB Signaling Pathway by 3,5-Bis(2-flurobenzylidene)piperidin-4-one (EF24), a Novel Monoketone Analog of Curcumin,” Molecular Pharmacology, Vol. 74, No. 3, 2008, pp. 654-661. doi:10.1124/mol.108.046201
[54] K. M. Youssef, M. A. El-Sherbeny, F. S. El-Shafie, H. A. Farag, O. A. Al-Deeb and S. A. A. Awadalla, “Synthesis of Curcumin Analogues as Potential Antioxidant, Cancer Chemopreventive Agents,” Archiv der Pharmazie, Vol. 337, No. 1, 2004, pp. 42-54. doi:10.1002/ardp.200300763
[55] K. M. Youssef and M. A. El-Sherbeny, “Synthesis and Antitumor Activity of Some Curcumin Analogs,” Archiv der Pharmazie, Vol. 338, No. 4, 2005, pp. 181-189. doi:10.1002/ardp.200400939
[56] H. Ohori, H. amakoshi, M. Tomizawa, M. Shibuya, Y. Kakudo, A. Takahashi, S. Takahashi, S. Kato, T. Suzuki, C. shioka, Y. Iwabuchi and H. Shibata, “Synthesis and Biological Analysis of New Curcumin Analogues Bearing an Enhanced Potential for the Medicinal Treatment of Cancer,” Molecular Cancer Therapeutics, Vol. 5, 2006, pp. 2563-2571. doi:10.1158/1535-7163.MCT-06-0174
[57] H. Shibata, H. Yamakoshi, A. Sato, H. Ohori, Y. Kakudo, C. Kudo, Y. Takahashi, M. Watanabe, H. Takan, C. Ishioka, T. Noda and Y. Iwabuch, “Newly Synthesized Curcumin Analog has Improved Potential to Prevent Colorectal Carcinogenesis in Vivo,” Cancer Science, Vol. 100, No. 5, 2009, pp. 956-960. doi:10.1111/j.1349-7006.2009.01127.x
[58] H. Chandru, A. C. Sharada, B. K. Bettadaiah, C. S. A. Kumar, K. S. Rangappa, Sunila and K. Jayashree, “In Vivo Growth Inhibitory and Anti-Angiogenic Effects of Synthetic Novel Dienone Cyclopropoxy Curcumin Analogs on Mouse Ehrlich Ascites Tumor,” Bioorganic & Medicinal Chemistry, Vol. 15, No. 24, 2007, pp. 7696-7703. doi:10.1016/j.bmc.2007.08.051
[59] J. R. Fuchs, B. Pandit, D. Bhasin, J. P. Etter, N. Regan, D. Abdelhamid, C. Li, J. Lin and P. K. Li, “Structure-Activity Relationship Studies of Curcumin Analogues,” Bioorganic & Medicinal Chemistry Letters, Vol. 19, No. 7, 2009, pp. 2065-2069. doi:10.1016/j.bmcl.2009.01.104
[60] B. Yadav, S. Taurin, R. J. Rosengren, M. Schumacher, M. Diederich, T. J. Somers-Edgar and L. Larsen, “Synthesis and Cytotoxic Potential of Heterocyclic Cyclohexanone Analogues of Curcumin,” Bioorganic & Medicinal Chemistry, Vol. 18, No. 18, 2010, pp. 6701-6707. doi:10.1016/j.bmc.2010.07.063
[61] H. Yamakoshi, H. Ohori, C. Kudo, A. Sato, N. Kanoh, C. Ishioka, H. Shibata and Y. Iwabuchi, “Structure-Activity Relationship of C5-Curcuminoids and Synthesis of Their Molecular Probes Thereof,” Bioorganic & Medicinal Chemistry, Vol. 18, No. 3, 2010, pp. 1083-1092. doi:10.1016/j.bmc.2009.12.045
[62] P. Lagisetty, P. Vilekar, K. Sahoo, S. Anant and V. Awasthi, “CLEFMA—An Anti-Proliferative Curcuminoid from Structure-Activity Relationship Studies on 3,5-Bis(benzylidene)-4-piperidones,” Bioorganic & Medicinal Chemistry, Vol. 18, No. 16, 2010, pp. 6109-6120. doi:10.1016/j.bmc.2010.06.055
[63] J. Xiao, Y. Chu, K. Hu, J. Wan, Y. Huang, C. Jiang, G. Liang and X. Li, “Synthesis and Biological Analysis of a New Curcumin Analogue for Enhanced Anti-Tumor Activity in HepG 2 Cells,” Oncology Reports, Vol. 23, No. 5, 2010, pp. 1435-1441. doi:10.3892/or_00000781
[64] S. S. Sardjiman, M. S. Reksohadiprodjo, L. Hakim, H. Goot and H. Timmerman, “1,5-Diphenyl-1,4-pentadiene-3-ones and Cyclic Analogues as Antioxidative Agents. Synthesis and Structure-Activity Relationship,” European Journal of Medicinal Chemistry, Vol. 32, No. 7-8, 1997, pp. 625-630. doi:10.1016/S0223-5234(97)83288-6
[65] K. H. Lee, F. H. A. Aziz, A. Syahida, F. Abas, K. Shaari, D. A. Israf and N. H. Lajis, “Synthesis and Biological Evaluation of Curcumin-Like Diarylpentanoid Analogues for Anti-In?ammatory, Antioxidant and Anti-Tyrosinase Activities,” European Journal of Medicinal Chemistry, Vol. 44, No. 8, 2009, pp. 3195-3200. doi:10.1016/j.ejmech.2009.03.020
[66] E. Simoni, C. Bergamini, R. Fato, A. Tarozzi, S. Bains, R. Motterlini, A. Cavalli, M. L. Bolognesi, A. Minarini, P. Hrelia, G. Lenaz, M. Rosini and C. Melchiorre, “Polyamine Conjugation of Curcumin Analogues toward the Discovery of Mitochondria-Directed Neuroprotective Agents,” Journal of Medicinal Chemistry, Vol. 53, No. 19, 2010, pp. 7264-7268. doi:10.1021/jm100637k
[67] C. Zhao, J. Yang, Y. Wang, D. Liang, X. Yang, X. Li, J. Wu, X. Wu, S. Yang, X. Li and G. Liang, “Synthesis of Mono-Carbonyl Analogues of Curcumin and Their Effects on Inhibition of Cytokine Release in LPS-Stimulated RAW 264.7 Macrophages,” Bioorganic & Medicinal Chemistry, Vol. 18, No. 7, 2010, pp. 2388-2393. doi:10.1016/j.bmc.2010.03.001
[68] A. M. Katsori, M. Chatzopoulou, K. Dimas, C. Kontogiorgis, A. Patsilinakos, T. Trangas and D. Hadjipavlou-Litina, “Curcumin Analogues as Possible Anti-Proliferative & Anti-In?ammatory Agents,” European Journal of Medicinal Chemistry, Vol. 46, No. 7, 2011, pp. 2722-2735. doi:10.1016/j.ejmech.2011.03.060
[69] G. Liang, S. Yang, L. Jiang, Y. Zhao, L. Shao, J. Xiao, F. Ye, Y. Li and X. Li, “Synthesis and Anti-Bacterial Properties of Mono-carbonyl Analogues of Curcumin,” Chemical Pharmaceutical Bulletin, Vol. 56, No. 2, 2008, pp. 162-167. doi:10.1248/cpb.56.162
[70] S. Y. Chen, Y. Chen, Y. P. Li, S. H. Chen, J. H. Tan, T. M. Ou, L. Q. Gu and Z. S. Huang, “Design, Synthesis, and Biological Evaluation of Curcumin Analogues as Multifunctional Agents for the Treatment of Alzheimer’s disease,” Bioorganic & Medicinal Chemistry, Vol. 19, No. 18, 2011, pp. 5596-5604. doi:10.1016/j.bmc.2011.07.033

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.